Sirna and Lilly Collaborate to Find RNAi-Based Cancer Therapeutics

Jan 27, 2004

NEW YORK, Jan. 27 (GenomeWeb News) - Sirna Therapeutics and Eli Lilly plan to develop RNAi therapeutics for cancer, the companies said today.

During the eighteen-month collaboration, the companies will test Sirna's small interfering RNAs against oncology targets from Lilly.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Not Always an Answer

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

CRISPR Acceptance or Not?

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

This Week in Science

In Science this week: research regulation and reporting requirement reform, and more.

Building Up Numbers

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Main menu